Gsk Share Discussion Threads

[buywell3] 23/12/2018 23:20

One day perhaps you won't see

The scale of the source of transmissible prion disease

Corneal pathology is the second leading cause of blindness worldwide with 20-30 million patients in need of a remedy and around 2 million new cases/year

[buywell3] 23/12/2018 22:16

....... Alzheimers' , Parkinsons are Prion Diseases and Transmissible ..........

IMO

No cure exists , hence GSK and AZN and many others have wasted Billions looking for a drug that doesn't and will never be found






The NHS knows that CJD and vCJD are prion diseases and that vCJD was transmissible by the use of prion protein residue contaminated surgical instruments being used , after the NHS cleaning/washing process ( ie not properly tested/inadequate thus transmitting vCJD from patient to patient.


The NHS has stated there are 1 in every 2000 people carrying vCJD ( or prions ) now as I key.




This is a low number they say ... but it means even on the NHS estimate that aound a minimum of 10,000 vCJD carriers in the UK ... who are having operations / using dental equipment / and having more worringly as I will explain Eye inspections and eye surgery.


The true number of carriers is in fact much higher because a more variant form of the prions associated with vCJD has recently been identified that was not tested for in the old 1 in 2000 test. More than double the incidence is therefore likely ie probably a minimum of 30,000 carriers.


However sCJD is even more common than vCJD , is a prion disease and transmissible , and in November of this year has been identified in the eyes of humans on the surface of corneas.

It’s unknown how early in the disease process prions appear in the eyes of humans, but in rodents, they are present prior to the onset of disease. About 40% of sCJD patients develop eye-related symptoms serious enough to warrant a consultation with an ophthalmologist. Somwhere between a quarter and a half go blind.

Undiagnosed CJD patients may seek testing. And the diagnostic equipment used to test them may then become contaminated, the authors write. They recommend single-use instruments or the adoption of new decontamination procedures for opthalmological equipment with better effectiveness on prions.

''corneal transplants are becoming increasingly popular worldwide. According to the authors of the link below , 185,576 were performed in 116 countries in 2012, a new high. The United States leads the world per capita, with 64,000 performed each year''


IMO Alzheimers and Parkinsons are being transmitted from person to person via both corneal transplants and protein reside contaminated surgical instruments and test equipment used in both the Neurology and Ophthalmology Depts of the NHS

[patientcapital] 22/12/2018 23:01

J, no but we were brokers to ICI when it split. Most of my colleagues switched Zeneca into additional ICI. For my clients I did the opposite. Also invested quite heavily into Wellcome.

I suspect the MMC would have had something to say about a Zantac, Tagamet, Losec combination at that time.

[alphorn] 21/12/2018 18:08

J - he may have had an issue with AZN PPI's? From memory it was quite a spat? Then followed with a project for ranitidine bismuth citrate...…230;……...

[jadeticl3] 21/12/2018 17:59

PCap, did you know RBS? I knew him well. He wanted to buy Zeneca instead of them merging with Astra, but they were not willing! Where would GLAXOZENECA be now if that had happened?

[montyhedge] 21/12/2018 15:01

Next quarterly dividend ex Feb 23p. This share just keeps on giving, lol.

[tradermichael] 21/12/2018 12:58

The 68% stake that GSK will have in the joint venture presumably takes into account the loss of sales from Horlicks etc. Otherwise, the GSK CH sales (in 2017 being £7.8 bill) would represent 79.6% of the combined CH sales of £9.8 bill.

[tradermichael] 21/12/2018 12:51

Then ….. next Q4 Ex-dividend date is Thursday 21 February 2019

[patientcapital] 21/12/2018 12:48

I’ve held these since pre penbritin. While the CEO is no Sykes she is moving in the right direction. A merger with AZN would be his preferred route. Mine as well.

[tradermichael] 21/12/2018 12:48

Yes, next dividend(Q3) pays out 10 January. Not long now, and not long before I buy some more with it (current price is a gift)!

[montyhedge] 21/12/2018 12:38

GSK my share for 2019, dividend cheque on the doormat every 13 weeks, while we wait for 1775p.

[montyhedge] 21/12/2018 09:19

That's what it should be in a normal market, unfortunately these markets are not normal at the moment. Dow 500 point swings.

[gbh2] 21/12/2018 08:53

Looks like the wrong kind of Turkey this Christmas :(

[oriana2] 20/12/2018 17:53

So.......

What will be the share price this time next year????


:)

[philanderer] 20/12/2018 16:07

'GSK's Pfizer deal is just a small step towards fixing its share price'

[gbh2] 20/12/2018 13:48

Edit, share price playing games.

[pip_uk] 20/12/2018 13:34

I was lucky I suddenly came within the governments target age range so it cost me nothing.

[montyhedge] 20/12/2018 13:26

EssStill looks good value, in a normal market, GSK would have gone back to their years high 1725p. Apart from transforming deal, it's the Shingles vaccine which is great. From nothing to Blockbuster meaning 1 billion dollars.I paid private 130 pounds for the shingles vac. In US tv advertising been stopped, they can't keep up with demand. 1 in 3 sometime in their life will get shingles.

[essentialinvestor] 20/12/2018 12:40

FFS, I would have much preferred it continued falling today, not to be.
Never cheer when prices go up if you have cash to invest!. Much prefer down days.

[montyhedge] 20/12/2018 11:38

Surprised not over 1600p on this transforming deal, the city been on about this for years, now CEO has delivered what do they want, I suppose with the FTSE 100 low, buyers not there. In the meantime collect a nice dividend every 13 weeks.

[montyhedge] 20/12/2018 10:21

Under 1500p looks like a gift from the stockmarket gods, 1635p in the New Year, this is a transforming deal for GSK, just like CEO said.